This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous Mircera for the maintenance of hemoglobin levels in hemodialysis patients with chronic renal anemia. Patients will receive 4-weekly intravenous injections of Mircera, at a starting dose of 120, 200 or 360 micrograms. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
132
120, 200 or 360 micrograms iv every 4 weeks (starting dose)
Cukurova University Medical Faculty; Internal Medicine
Adana, Turkey (Türkiye)
Percentage of Participants Who Maintained Their Mean Hemoglobin Concentration Within +/- 1.0 Gram/Deciliter of Their Reference Hemoglobin Concentration and Between 10.0 and 12.0 Gram/Deciliter During the Efficacy Evaluation Period
The reference hemoglobin (Hb) value was taken as the time adjusted average of all Hb assessments during the SVP (Week -4 to Week 0). The time adjusted average Hb concentration of all the values recorded during the efficacy evaluation period (EEP) was calculated for each participant and their reference Hb concentration was subtracted from this value. The percentage of participants maintaining their average Hb concentration during the EEP within +/- 1 gram/deciliter (g/dL) of their reference Hb concentration and between the Hb range 10.0 -12.0 g/dL is presented. The EEP was defined as Week 16 to Week 24. Data missing at the end of the EEP was handled using the last value carried forward method, including any data missing due to withdrawal of participants following red blood cells (RBC) transfusion.
Time frame: EEP (Week 16 to Week 24)
Mean Change in Hemoglobin Concentration Between the Stability Verification Period and the Efficacy Evaluation Period
The mean change in the time-adjusted average Hb concentration between the two study periods The Stability Verification Period (SVP) and EEP is presented. The SVP was defined as Week -4 to Week 0. The EEP was defined as Week 16 to Week 24.
Time frame: SVP (Week -4 to Week 0) and EEP (Week 16 to Week 24)
Percentage of Participants Maintaining Hemoglobin Concentration Within the Range of 10.0-12.0 Gram/Deciliter Throughout the Efficacy Evaluation Period
The time adjusted average Hb concentration of all the values recorded during the EEP was calculated for each participant. The percentage of participants maintaining their average Hb concentration during the EEP within the Hb concentration range of 10.0-12.0 g/dL is presented. The EEP was defined as Week 16 to Week 24.
Time frame: EEP (Week 16 to Week 24)
Median Time Spent in the Hemoglobin Range 10.0-12.0 Gram/Deciliter During the Efficacy Evaluation Period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ankara Research and Training Hospital; The Clinic of Nephrology
Ankara, Turkey (Türkiye)
Ankara University School of Medicine; Nephrology
Ankara, Turkey (Türkiye)
Faith University School of Medicine; Nephrology
Ankara, Turkey (Türkiye)
Hacettepe University Medical Faculty; Department of Internal Medicine
Ankara, Turkey (Türkiye)
Baskent University Hospital; Transplantation
Ankara, Turkey (Türkiye)
Gazi University School of Medicine; Nephrology
Ankara, Turkey (Türkiye)
Adnan Menderes Uni School of Medicine; Physical Therapy & Rehabilitation
Aydin, Turkey (Türkiye)
Dicle Uni Medical Faculty; Internal Medicine
Diyarbakır, Turkey (Türkiye)
Trakya University Medical Faculty; Internal Medicine; Nephrology
Edirne, Turkey (Türkiye)
...and 10 more locations
The Hb concentration was recorded for all the participants during the EEP. The median time spent (in days) by participants in the target range (10.0-12.0 g/dL) during the EEP is presented. The EEP was defined as Week 16 to Week 24.
Time frame: EEP (Week 16 to Week 24)
Mean C.E.R.A. Dose Required to Maintain Hemoglobin Level Within the Range 10.0-12.0 Gram/Deciliter Throughout the Efficacy Evaluation Period
The mean dose of C.E.R.A. required to maintain Hb level between 10.0-12.0 g/dL during the EEP was calculated per participant and then summarized. The EEP was defined as Week 16 to Week 24. However, C.E.R.A. was not administered at the Week 24 visit. Therefore, the time period for calculation of mean C.E.R.A. dose during EEP is from Week 16 to Week 20.
Time frame: EEP (Week 16 to Week 20)
Percentage of Participants Requiring Any Dose Adjustments in C.E.R.A. During the Dose Titration Period and Efficacy Evaluation Period
Dose adjustments were necessary when Hb increased or decreased by a clinically significant amount. The dose of C.E.R.A. was adjusted to maintain the individual participant's Hb within a range of +/- 1.0 g/dL of the reference Hb concentration and between 10.0 and 12.0 g/dL throughout the dose titration period (DTP) and the EEP (Week 1 to Week 24). The reference Hb value was taken as the time adjusted average of all Hb assessments during the SVP (Week -4 to Week 0).
Time frame: DTP (Week 1 to Week 16), EEP (Week 16 to Week 24)
Mean Monthly Dose of C.E.R.A. During the Dose Titration Period and Efficacy Evaluation Period
The mean monthly dose of C.E.R.A. administered during the DTP and EEP was calculated per participant and then summarized.
Time frame: DTP (Week 1 to Week 16), EEP (Week 16 to Week 24)
Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume at Week 16 and Week 24
Mean change from Baseline in erythrocyte mean corpuscular volume (MCV) was calculated as the value at a specific week during the study minus the BL value. The Baseline was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change From Baseline in Hematocrit at Week 16 and Week 24
The hematocrit, also called packed cell volume or erythrocyte volume fraction, is the volume percentage of red blood cells in the blood. Mean change from Baseline (BL) in hematocrit was calculated as the value at a specific week during the study minus the BL value. The BL was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change From Baseline in Hemoglobin at Week 16 and Week 24
Mean change from BL in hemoglobin was calculated as the value at a specific week during the study minus the BL value. The BL was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change From Baseline in Leucocytes and Platelet at Week 16 and Week 24
Mean change from BL in for each parameter (leucocytes and platelet) was calculated as the value at a specific week during the study minus the BL value. The BL was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change From Baseline in Ferritin at Week 16 and Week 24
Mean change from BL in ferritin was calculated as the value at a specific week during the study minus the BL value. The BL was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change From Baseline in Iron, Total Iron Binding Capacity, and Creatinine at Week 16 and Week 24
Mean change from BL in each parameter \[iron, total iron binding capacity (TIBC), and creatinine\] was calculated as the value at a specific week during the study minus the BL value. The BL was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change From Baseline in Transferrin and Albumin at Week 16 and Week 24
Mean change from BL in each parameter (transferrin and albumin) was calculated as the value at a specific week during the study minus the BL value. The BL was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change From Baseline in Transferrin Saturation at Week 16 and Week 24
Mean change from BL in transferrin saturation (TSAT) was calculated as the value at a specific week during the study minus the BL value. The BL was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change From Baseline in C-Reactive Protein at Week 16 and Week 24
Mean change from BL in C-reactive protein was calculated as the value at a specific week during the study minus the BL value. The BL was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change From Baseline in Phosphate and Potassium at Week 16 and Week 24
Mean change from BL in each parameter (phosphate and potassium) was calculated as the value at a specific week during the study minus the BL value. The BL was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change From Baseline in Weight at Week 16 and Week 24
Mean change from BL in weight was calculated as the value at a specific week during the study minus the BL value. The BL was defined as Week -4 to Week 0.
Time frame: BL (Week -4 to Week 0), Week 16, and Week 24
Mean Change in From Baseline in Blood Pressure at Week 16 and Week 24
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured before blood sampling and C.E.R.A. administration. Blood pressure was assessed both before and after the dialysis session for participants undergoing hemodialysis. Change from BL in blood pressure was calculated as the value at a specific week (W) during the study minus the BL value. The baseline was defined as Week -4 to Week 0.
Time frame: Baseline (Week -4 to Week 0), Week 16, and Week 24
Number of Participants Taking Concomitant Medications
The number of participants taking different classes of concomitant medications at any time following enrollment into the study is presented.
Time frame: Up to Week 28
Number of Participants With Any Adverse Events and Serious Adverse Events
An adverse event (AE) is any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
Time frame: Up to Week 28
Number of Participants With Reports of Anti-erythropoietin Antibodies
The number of participants with Anti-epoetin antibodies is presented.
Time frame: Up to Week 24
Number of Participants Who Received Red Blood Cell Transfusions During the Dose Titration Period and Efficacy Evaluation Period
Red blood cell transfusions were permitted during the DTP and EEP (Week 1 to Week 24) in case of medical need. All participants requiring a blood transfusion were withdrawn from the study. The number of participants who were administered RBC transfusions during the DTP and EEP is presented.
Time frame: Week 1 to Week 24